Cellectis (CLLS) Treasury Shares (2013 - 2022)

Cellectis' (CLLS) quarterly Treasury Shares came in at -$1.0 million in Q4 2022, little changed quarter-over-quarter from -$1.0 million in Q1 2022.

Cellectis (CLLS) Treasury Shares (2013 - 2022) Analysis & Trends

Cellectis' Treasury Shares history runs 1 years deep, the most recent figure standing at -$1.0 million for Q4 2022.

On a quarterly basis, Treasury Shares rose 198.34% year-over-year to $297000.0 in Q3 2018; TTM through Sep 2018 was $297000.0, a 198.34% increase from a year earlier, with the FY2017 full-year figure at -$297000.0, down 171.39% from the prior year.
Treasury Shares climbed to $297000.0 in Q3 2018 per CLLS's latest filing, from -$587000.0 in the prior quarter.
Across five years, Treasury Shares topped out at -$1.0 million in Q1 2022 and bottomed at -$1.0 million in Q1 2022.
The 5-year median for Treasury Shares is -$209222.0 (2016), against an average of -$82821.6.
Biggest YoY gain for Treasury Shares was 198.34% in 2018; the steepest drop was 601.71% in 2018.
Year by year, Treasury Shares stood at $313708.2 in 2014, then tumbled by 35.71% to $201685.6 in 2015, then surged by 64.35% to $331475.3 in 2016, then sank by 189.6% to -$297000.0 in 2017, then soared by 200.0% to $297000.0 in 2018.
Per Business Quant, the three latest CLLS Treasury Shares figures stand at $297000.0 (Q3 2018), -$587000.0 (Q2 2018), and -$373000.0 (Q1 2018).

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-21,709.08
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	265,401.92
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	19.41 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	5.14 Mn
10	Cellectis	281.48 Mn	95.81 Mn	-	-

Download Data